The results of I-125 brachytherapy in patients of moderate-risk prostate cancer

Background: The treatment for moderate-risk prostate cancer patients include several methods. There are radical prostatectomy, radiotherapy, brachytherapy, cryotherapy, hormone therapy, and dynamic observation. Purpose: The goal of our study was to analyze the results of brachytherapy using I-125 in patients with moderate-risk prostate cancer. Materials and methods: Eighty six patients at the age of 48 to 76 (median 66 years) were included in the analysis. Implantation of iodine-125 sources was performed in all patients. The total dose to the prostate was 145 Gy. PSA monitoring after surgery was performed every 3 months during the first year, then every 6 months for the next 3 years, and then – annually. Survival was estimated using the Kaplan – Meier scale considering such factors as age, the D90 to the prostate, the V100 prostate, preoperative anti-androgen therapy. Quality of life analysis was made using standard IPSS questionnaire. Results: 5‑year results with median follow-up of 60 months without PSA-recurrent, tumor-specific and overall survival were 90.5%, 100% and 95.2%, respectively. The treatment method has an acceptable spectrum of complications. 1st degree urethritis in the category of RTOG within 1 month after the operation developed in 60 (69.3%) patients while in the 6‑month follow-up period the symptoms of dysuria had only 11 (13.3%) patients, which was associated with chronic urinary infection, resistant to antibiotic therapy. 1st degree radiation proctitis within 1 month after the operation developed in 2 (2.1%) patients, and after 6‑month observation period the symptoms of proctitis ceased in all patients. Before the treatment, the number of points on the IPSS scale was 0–7 points – n = 63 (74%), 8–19 points – n = 23 (26%) (median IPSS 5.7). A month later, the number of patients with mild symptomatology increased to 69.3%, 6 months after the end of treatment, the mean IPSS was 10 points. After 12 months, 0–7 points were recorded in 94% of patients. Conclusion: The permanent brachytherapy with I-125 in patients with moderate-risk prognosis showed very good functional and oncological outcomes. This method provides excellent control of the PSA level with median follow-up of 65 months, and at the same time provides high quality of urination for 2–3 years after treatment.

1. Ferlay J. et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012, Int. J. Cancer, 2015, Vol. 136, E359.

2. Злокачественные новообразования в России в 2015 году (заболеваемость и смертность). Под ред. А. Д. Каприна, В. В. Старинского, Г. В. Петровой. М.: МНИОИ им. П. А. Герцена, филиал ФГБУ «НМИРЦ» Минздрава России. 2017. 250 с. ISBN 978-5-85502-227-8. [Zlokachestvennye novoobrazovaniya v Rossii v 2015 godu (zabolevaemosti smertnost). Eds. A. D. Kaprin, V. V. Starinskii, G. V. Petrova. Moscow: MNIOI im. P. A. Gertsena, filial FGBU «NMIRTS» Minzdrava Rossii. 2017. 250 p. ISBN 978-5-85502-227-8].

3. Cooperberg M. R. et al. The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy, J. Urol., 2005, Vol. 173, p. 1938.

4. http://oncology-association.ru / docs / recomend / may2015 / 39vz-rek. pdf.

5. Heidenreich A. et al. Рак предстательной железы Перевод: О. В. Антонова. Научное редактирование: Б. Я. Алексеев, К. М. Нюшко // ЕАУ. 2010. – Modeofaccess: http://www.uroweb.org / gls / pdf / russian / 3_ Prostate_Cancer.pdf. Dateofaccess: 06.03.2013.

6. Grimm P., Billiet I., Bostwick D. et al. Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group, BJU Int., 2012 Feb, Vol. 109, Suppl. 1, pp. 22–29.

7. Lee W. R., DeSilvio M., Lawton C., Gillin M., Morton G., Firat S., Baikadi M., Kuettel M., Greven K., Sandler H. A phase II study of external beam radiotherapy combined with permanent source brachytherapy for intermediate-risk, clinically localized adenocarcinoma of the prostate: Preliminary results of RTOG P-0019, Int. J. Radiat. Oncol. Biol. Phys., 2006, Vol. 64, No. 3, pp. 804–809.

8. Feigenberg S. J., Lee W. R., Desilvio M. L., Winter K., Pisansky T. M., Bruner D. W., Lawton C., Morton G., Baikadi M.,

9. Sandler H. Health-related quality oflife in men receiving prostate brachytherapy on RTOG 98–05, Int. J. Radiat. Oncol. Biol. Phys., 2005, Vol. 62, No. 4. pp. 956–964

10. Crook J. M., Gomez-Iturriaga A., Wallace K., Ma C., Fung S., Alibhai S., Jewett M., Fleshner N. Comparison of health-related quality of life 5 years aer SPIRIT: Surgical Prostatectomy Versus Interstitial Radiation Intervention, Trial. J. Clin. Oncol., 2011, Vol. 29, No. 4, pp. 362–368

11. Hurwitz M. D., Halabi S., Ou S. S., McGinnis L. S., Keuttel M. R., Dibiase S. J., Small E. J. Combination external beam radiation and brachytherapy boost with androgen suppression for treatment of intermediate-risk prostate cancer: An initial report of CALGB 99809, Int. J. Radiat. Oncol. Biol. Phys., 2008, Vol. 72, No. 3, pp. 814–819.

12. Blasko J. C., Grimm P. D., Sylsvester J. E., Cavanagh W. The role of external beam radiotherapy with I-125 / Pd-103 brachytherapy for prostate carcinoma, Radiother. Oncol., 2000, Vol. 57 (3), pp. 273–278.

13. Potters L., Morgenstern C., Calugaru E. et al. 12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer. J. Urol., 2005, Vol. 173 (5), pp. 1562–1566.

14. Stone N. N., Stone M. M., Rosenstein B. S. et al. Influence of pretreatment and treatment factors on intermediate to long-term outcome after prostate brachytherapy, J. Urol., 2011, Vol. 185 (2), pp. 495–500.

15. Grimm P. D., Blasko J. C., Sylvester J. E. et al. 10-year biochemical (prostate-specific antigen) control of prostate cancer with 125-I brachytherapy, Int. J. Radiat. Biol. Phys., 2001, Vol. 51 (1), pp. 31–40.

16. Potters L., Klein E. A., Kattan M. W. et al. Monotherapy for stage T1-T2 prostate cancer: radical prostatectomy, external beam radiotherapy, or permanent seed implantation, Radiother. Oncol., 2004, Vol. 71 (1), pp. 29–33.

17. Sylvester J. E., Blasko J. C., Grimm R. et al. Fifteen year follow-up of the first cohort of localized prostate cancer patients treated with brachytherapy, J. Clin. Oncol., 2004, Vol. 22 (14), pp. 45–67.

18. Stone N. N., Stock R. G., Unger P. Intermediate term biochemical-free progression and local control following 125-iodine brachytherapy for prostate cancer, J. Urol., 2005, Vol. 173 (3), pp. 803–807.

19. Lawton C. A., DeSilvio M., Lee W. R. et al. Results of a phase II trial of transrectal ultrasound-guided permanent radioactive implantation of the prostate for definitive management of localized adenocarcinoma of the prostate (RTOG 98-05), Int. J. Radiat. Oncol. Biol. Phys., 2007, Vol. 67 (1), pp. 39–47.

20. Grimm P. D., Blasko J. C., Sylvester J. E. et al. 10-year biochemical (prostate-specific antigen) control of prostate cancer with 125-I brachytherapy, Int. J. Radiat. Biol. Phys., 2001, Vol. 51 (1), pp. 31–40.

21. Roeloffzen E. M., Battermann J. J., van Deursen M. J. et al. Influence of dose on risk of acute urinary retention after iodine-125 prostate brachytherapy, Int. J. Radiation. Oncology. Biol. Phys., 2011, Vol. 80, pp. 1072–1079.